- Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar
- Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)
- Amneal Releases 2023 Environmental, Social and Governance Report
- Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies
- Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California
- Amneal to Participate at Upcoming Investor Conference
- Amneal Reports First Quarter 2024 Financial Results
- Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
- Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
- Amneal to Report First Quarter 2024 Results on May 3, 2024
More ▼
Key statistics
On Friday, Amneal Pharmaceuticals Inc (AMRX:NSQ) closed at 6.67, -8.00% below its 52-week high of 7.25, set on Jun 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.74 |
---|---|
High | 6.74 |
Low | 6.60 |
Bid | 6.30 |
Offer | 6.80 |
Previous close | 6.75 |
Average volume | 2.21m |
---|---|
Shares outstanding | 308.65m |
Free float | 120.40m |
P/E (TTM) | -- |
Market cap | 2.08bn USD |
EPS (TTM) | -0.5642 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 21:00 BST.
More ▼